OBJECTIVES: IQ motif containing GTPase-activating protein 1 (IQGAP1) acts as a scaffold for aberrant mitogen-activated protein kinase (MAPK) signaling driven by KRAS mutations in pancreatic ductal adenocarcinoma (PDAC). We determined the role of IQGAP1 in clonogenic growth and metastasis in PDAC. METHODS: We inhibited IQGAP1 expression using shRNA and assessed clonogenic growth, cell migration, and MAPK signaling in vitro and tumor initiation and metastasis in vivo. The efficacy of a peptide mimicking the IQGAP1 WW domain that binds and inhibits ERK1/2 was determined in vitro and in vivo. RESULTS: IQGAP1 loss inhibited clonogenic growth and migration of KRAS-dependent PDAC cells by disrupting MAPK signaling. In mice, IQGAP1 knockdown decreased tumor-initiating cell frequency and metastasis. WW peptide treatment inhibited clonogenic growth and in vivo tumor growth. CONCLUSIONS: Pancreatic ductal adenocarcinoma clonogenic growth, metastasis, and tumor initiation are dependent on MAPK signaling via IQGAP1. Treatment with a WW peptide disrupts IQGAP1 function and represents a novel targeting strategy for PDAC.
OBJECTIVES:IQ motif containing GTPase-activating protein 1 (IQGAP1) acts as a scaffold for aberrant mitogen-activated protein kinase (MAPK) signaling driven by KRAS mutations in pancreatic ductal adenocarcinoma (PDAC). We determined the role of IQGAP1 in clonogenic growth and metastasis in PDAC. METHODS: We inhibited IQGAP1 expression using shRNA and assessed clonogenic growth, cell migration, and MAPK signaling in vitro and tumor initiation and metastasis in vivo. The efficacy of a peptide mimicking the IQGAP1 WW domain that binds and inhibits ERK1/2 was determined in vitro and in vivo. RESULTS:IQGAP1 loss inhibited clonogenic growth and migration of KRAS-dependent PDAC cells by disrupting MAPK signaling. In mice, IQGAP1 knockdown decreased tumor-initiating cell frequency and metastasis. WW peptide treatment inhibited clonogenic growth and in vivo tumor growth. CONCLUSIONS:Pancreatic ductal adenocarcinoma clonogenic growth, metastasis, and tumor initiation are dependent on MAPK signaling via IQGAP1. Treatment with a WW peptide disrupts IQGAP1 function and represents a novel targeting strategy for PDAC.
Authors: Zohar Sachs; Rebecca S LaRue; Hanh T Nguyen; Karen Sachs; Klara E Noble; Nurul Azyan Mohd Hassan; Ernesto Diaz-Flores; Susan K Rathe; Aaron L Sarver; Sean C Bendall; Ngoc A Ha; Miechaleen D Diers; Garry P Nolan; Kevin M Shannon; David A Largaespada Journal: Blood Date: 2014-10-14 Impact factor: 22.113
Authors: Zeshaan A Rasheed; Jie Yang; Qiuju Wang; Jeanne Kowalski; Irwin Freed; Christopher Murter; Seung-Mo Hong; Jan-Bart Koorstra; N V Rajeshkumar; Xiaobing He; Michael Goggins; Christine Iacobuzio-Donahue; David M Berman; Daniel Laheru; Antonio Jimeno; Manuel Hidalgo; Anirban Maitra; William Matsui Journal: J Natl Cancer Inst Date: 2010-02-17 Impact factor: 13.506
Authors: Antonio Jimeno; Georg Feldmann; Ana Suárez-Gauthier; Zeshaan Rasheed; Anna Solomon; Gang-Ming Zou; Belen Rubio-Viqueira; Elena García-García; Fernando López-Ríos; William Matsui; Anirban Maitra; Manuel Hidalgo Journal: Mol Cancer Ther Date: 2009-01-27 Impact factor: 6.261
Authors: Christian B Gocke; Ross McMillan; Qiuju Wang; Asma Begum; Vesselin R Penchev; Syed A Ali; Ivan Borrello; Carol Ann Huff; William Matsui Journal: Mol Cancer Ther Date: 2016-08-29 Impact factor: 6.261
Authors: Roberto Pallini; Lucia Ricci-Vitiani; Giuseppe Luigi Banna; Michele Signore; Dario Lombardi; Matilde Todaro; Giorgio Stassi; Maurizio Martini; Giulio Maira; Luigi Maria Larocca; Ruggero De Maria Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531